NCD / LCD Information
Medicare/Medicaid Coverage - Billing lab charges to CMS
- Only tests that are medically necessary for the diagnosis or treatment of the patient should be ordered, along with the diagnosis that supports testing. Medicare does not pay for screening tests, except for certain specifically-approved procedures and may not pay for non-FDA approved tests or those tests considered experimental.
- Please inform the patient if there is a reason to believe that Medicare will not pay for a test. The patient should sign an ABN (Advanced Beneficiary Form), at this time to indicate that they will be responsible for the cost of the test if Medicare denies payment.
- The ordering physician must provide an ICD-10 numeric diagnosis code. If the physician does not, the laboratory will contact the physician for a valid ICD-10 numeric diagnosis code.
- Organ or disease-oriented panels should be billed to Medicare only when every component is medically necessary.
Local Coverage Decision
- Allergy Testing (You'll need to accept the site terms before viewing.)
- Blood Product Molecular Antigen Typing
- Breast Cancer Assay: Prosigna®
- Breast Cancer Index® (BCI) Gene Expression Test
- Decision Dx-UM (Uveal Melanoma)
- EndoPredict® Breast Cancer Gene Expression Test
- Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test
- Genetic Testing for Hypercoagulability/Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR) (L36400)
- HLA-DQB1*06:02 Testing for Narcolepsy
- Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer
- Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
- Melanoma Risk Stratification Molecular Testing
- MGMT Promoter Methylation Analysis
- Minimal Residual Disease Testing for Cancer
- MolDX: Biomarkers in Cardiovascular Risk Assessment (L36523)
- MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease (L36815)
- Molecular Assays for the Diagnosis of Cutaneous Melanoma
- Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer
- Molecular Diagnostic Testing
- Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing
- Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia
- Molecular Testing for Solid Organ Allograft Rejection
- myPath® Melanoma Assay
- Next-Generation Sequencing for Solid Tumors
- Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies
- NRAS Genetic Testing
- Oncotype DX® Breast Cancer for DCIS (Genomic Health™)
- Percepta® Bronchial Genomic Classifier
- Pharmacogenomics Testing
- Phenotypic Biomarker Detection from Circulating Tumor Cells
- Pigmented Lesion Assay
- Plasma-Based Genomic Profiling in Solid Tumors
- Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer
- Prognostic and Predictive Molecular Classifiers for Bladder Cancer
- Prometheus IBD sgi Diagnostic® Policy
- Prostate Cancer Genomic Classifier Assay for Men with Localized Disease
- Qualitative Drug Testing
- Repeat Germline Testing
- Vitamin D Testing